Table 3 Association between statin use before diagnosis and breast cancer-specific and all-cause mortality in patients with breast cancer
From: Statin use and breast cancer survival: a nationwide cohort study in Scotland
Breast cancer mortality | Patients | Person years | Age-adjusted HR (95 % CI) | P | Adjusteda HR (95 % CI) | P | |
|---|---|---|---|---|---|---|---|
[n = 12,231] | [n = 12,230] | ||||||
Breast cancer mortality | |||||||
Statin non-user | 834 | 9,200 | 29,298 | 1.00 (ref. cat.) | 1.00 (ref. cat.) | ||
Statin user | 381 | 3,031 | 9,125 | 0.98 (0.86, 1.11) | 0.71 | 0.85 (0.74,0.98) | 0.03 |
Simvastatin non-user | 963 | 10,175 | 32,229 | 1.00 (ref. cat.) | 1.00 (ref. cat.) | ||
Simvastatin user | 252 | 2,056 | 6,193 | 0.95 (0.83,1.09) | 0.48 | 0.87 (0.75,1.02) | 0.08 |
Lipophilic non-user | 961 | 10,168 | 32,212 | 1.00 (ref. cat.) | 1.00 (ref. cat.) | ||
Lipophilic user | 254 | 2063 | 6,211 | 0.96 (0.83,1.10) | 0.54 | 0.88 (0.76,1.02) | 0.09 |
Hydrophilic non-user | 1077 | 11,161 | 35,181 | 1.00 (ref. cat.) | 1.00 (ref. cat.) | ||
Hydrophilic user | 138 | 1,070 | 3,242 | 1.02 (0.85,1.21) | 0.87 | 0.90 (0.75,1.09) | 0.28 |
All-cause mortality | |||||||
Statin non-user | 1,340 | 9,200 | 29,298 | 1.00 (ref. cat.) | 1.00 (ref. cat.) | ||
Statin user | 691 | 3,031 | 9,125 | 0.96 (0.88,1.06) | 0.41 | 0.75 (0.67,0.84) | <0.001 |
Simvastatin non-user | 1,567 | 10,175 | 32,229 | 1.00 (ref. cat.) | 1.00 (ref. cat.) | ||
Simvastatin user | 464 | 2,056 | 6,192 | 0.95 (0.86,1.06) | 0.38 | 0.83 (0.74,0.92) | 0.001 |
Lipophilic non-user | 1,564 | 10,168 | 32,212 | 1.00 (ref. cat.) | 1.00 (ref. cat.) | ||
Lipophilic user | 467 | 2063 | 6211 | 0.96 (0.86,1.06) | 0.42 | 0.83 (0.75,0.93) | 0.001 |
Hydrophilic non-user | 1,788 | 11,161 | 35,181 | 1.00 (ref. cat.) | 1.00 (ref. cat.) | ||
Hydrophilic user | 243 | 1,070 | 3,242 | 0.98 (0.86,1.12) | 0.77 | 0.81 (0.70,0.93) | 0.002 |